| Study Reference |
Design |
No of Patients |
G-CSF Dose (μg/kg/day) |
Treatment Initiated |
Follow-Up |
Outcomes |
| [95] (MAGIC Trial) |
Phase-2, Randomised, Controlled |
n=7 BMNC; n=3 GCSF only; n=1 control |
10 for 4 days |
4 days prior to PCI |
6 months. |
GCSF treatment is safe. Increased CD34+ cell mobilization. GCSF alone has no functional benefit. BMNC transplantation significantly increased EF & ESV. Trial stopped due to significant restenosis rate. |
| [100] |
Non-randomised, Open-labelled |
n=14 GCSF; n=9 control |
10 for 7 days |
48 hours post-PCI |
3 and 12 months. |
GCSF is safe. Increased CD34+ cells/leukocytes. Trend towards increased EF and significant increase in WMS & perfusion vs. control. |
[96]
(FIRSTLINE-AMI trial) |
Randomised, Controlled |
n=25 GCSF; n=25 control |
10 for 6 days |
90 minutes post-PCI |
6 months. |
GCSF is safe. Increased CD34+ cell mobilization. EF, WMS & viability significantly improved vs. control. 4 & 5 patients in GCSF & control had restenosis, respectively. |
| [101] |
Randomised, placebo-controlled |
n=8 GCSF; n=8 control |
5 for 4 days |
37 hours post-PCI |
6 months. |
GCSF is safe. Increased mobilization of CD34+ cells. No significant benefit with lone GCSF. |
| [102] (G-CSF-STEMI Trial) |
Phase-2, Randomised, double-blind, placebo- controlled |
n=19 GCSF; n=21 control |
10 for 5 days |
32 hours post-PCI |
3 and 6 months. |
GCSF is safe. Increased CD34+ cells. No functional benefit with lone GCSF. No difference if restenosis rate vs. control. |
| [98] (REVIVAL-2 Trial) |
Randomised, Placebo-controlled |
n=56 GCSF; n=58 control |
10 for 5 days |
4-5 days post-PCI |
4-6 months. Angiography at |
GCSF is safe. Increased CD34+ cells. No functional benefit with lone GCSF. No difference in restenosis rate. |
| [99] (STEMMI Trial) |
Phase-2, randomised, double-blind, placebo-controlled |
n=33 GCSF; n=37 control |
10 for 6 days |
10-60 hours post-PCI |
6 months. |
GCSF is safe. Increased CD34+ cells and MSCs. No functional benefit with lone GCSF. No increase in restenosis rate with GCSF. |
